SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP issued a shareholder-solicitation notice reminding SPRY investors of a securities fraud class action with an October 5, 2026 lead plaintiff deadline. The complaint alleges ARS Pharmaceuticals misled investors about the timeline for insurance coverage of neffy, including risks around CVS Caremark's formulary addition.
Key figures
- Class period
- March 9, 2026 to June 24, 2026
- Lead plaintiff deadline
- October 5, 2026
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.